Chiusura precedente | 1,4300 |
Aperto | 1,4500 |
Denaro | 0,9600 x 4000 |
Lettera | 1,5300 x 3000 |
Min-Max giorno | 1,3300 - 1,4700 |
Intervallo di 52 settimane | 0,2100 - 1,6000 |
Volume | |
Media Volume | 3.956.435 |
Capitalizzazione | 862,766M |
Beta (5 anni mensile) | 1,57 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,1400 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 1,57 |
SEATTLE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the completion of recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01 (clinicaltrials.gov identifier NCT05655312), its targeted alpha-particle therapy, in development for the treatment of MC1R-positive metastatic melanoma. “We are encouraged by the pace of enrollment in the trial which we believe is indicativ
SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials (IIT) were presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium in Montreal, Canada, which was held October 4-6, 2023. Presentation One: Phase 1 Trial of Pb-212-VMT-alpha-NET in Select Metastatic or Inoperable Somatostatin Receptor Positive Tumors Summary: This presentation
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that long-term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer, as well as preliminary long-term data of Cesium-131 utilized in salvage tr